Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 9, 2011, Pages 1037-1040

  Clemmensen, A ^a   Spon, M ^a   Skov, L ^b,c   Zachariae, C ^b,c   Gniadecki, R ^a,c  

^a BISPEBJERG HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

drug adherence; efficacy; psoriasis; TNF inhibitors; ustekinumab

Indexed keywords

ADALIMUMAB; ETANERCEPT; USTEKINUMAB;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953111225     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03914.x     Document Type: Article

References (6)

1. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684. (Pubitemid 351671884)
2. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674. (Pubitemid 351671883)
3. Griffiths CE, Strober BE, van der Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-128.
4. Santos-Juanes J, Coto-Segura P, Mas-Vidal A, Osuna CG, Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumor necrosis factor therapies. Br J Dermatol 2010; 162: 1144-1146.
5. Karlsson JA, Kristensen LE, Kapetanovic MC, Gulfe A, Saxne T, Geborek P,. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 2008; 47: 507-513.
6. Orthonne J-P, Thaci D, Goldblum O, Chimenti S,. Responses to adalimumab in psoriasis patients previously treated with anti-tumor necrosis factor agents: subanalysis of BELIEVE. J Am Acad Dermatol 2010: 62 (Suppl. 1): AB130 (P3327).